BackAyala Pharmaceuticals Overview

Ayala Pharmaceuticals Total Current Liabilities

Track Ayala Pharmaceuticals's total current liabilities ($7.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$7.54M
16.44% YoYΔ $1.06M vs prior year quarter

Peer average

Loading

Ayala Pharmaceuticals Total Current Liabilities History

Loading

Ayala Pharmaceuticals vs. peers: Total Current Liabilities Comparison

Loading

Ayala Pharmaceuticals Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ayala Pharmaceuticals (AYLA) FAQ

Ayala Pharmaceuticals's total current liabilities stands at $7.5M as of December 2022. That compares with $6.5M in the prior-year period — up 16.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Ayala Pharmaceuticals reported $7.5M in total current liabilities versus $6.5M a year earlier — a 16.4% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $6.5M in the prior-year period — up 16.4% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Ayala Pharmaceuticals's total current liabilities evolved across reporting periods, while the comparison chart places AYLA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Ayala Pharmaceuticals's reading of $7.5M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.